TMPRSS2-ERG and RB1 as candidate predictive biomarkers for efficacy in TALAPRO-2: Phase 3 study of talazoparib (TALA) plus enzalutamide (ENZA) vs placebo (PBO) plus ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract

cited authors

  • Piulats, Josep M.; Azad, Arun A.; Laird, A. Douglas; Matsubara, Nobuaki; Fizazi, Karim; Shore, Neal D.; Karsh, Lawrence; Liu, Glenn; Fay, Andre P.; Carles, Joan; Jones, Robert J.; Voog, Eric; Zschabitz, Stefanie; De Giorgi, Ugo; Yip, Steven M.; Mu, Xinmeng Jasmine; Lin, Xun; Engelsberg, Arne; Agarwal, Neeraj

Publication Date

  • April 1, 2024

webpage

published in

category

volume

  • 84

issue

  • 7